دورية أكاديمية
أعرض في EDS

Can blood-based markers predict RECIST progression in non-small cell lung cancer treated with immunotherapy?

التفاصيل البيبلوغرافية
العنوان: Can blood-based markers predict RECIST progression in non-small cell lung cancer treated with immunotherapy?
المؤلفون: Yeghaian M; GROW Research Institute for Oncology and Reproduction, Maastricht University, Maastricht, The Netherlands.; Radiology Department, Netherlands Cancer Institute, Amsterdam, The Netherlands., Tareco Bucho TM; GROW Research Institute for Oncology and Reproduction, Maastricht University, Maastricht, The Netherlands.; Radiology Department, Netherlands Cancer Institute, Amsterdam, The Netherlands., de Bruin M; Radiology Department, Netherlands Cancer Institute, Amsterdam, The Netherlands., Schmitz A; Radiology Department, Netherlands Cancer Institute, Amsterdam, The Netherlands., Bodalal Z; GROW Research Institute for Oncology and Reproduction, Maastricht University, Maastricht, The Netherlands.; Radiology Department, Netherlands Cancer Institute, Amsterdam, The Netherlands., Smit EF; Pulmonology Department, Leiden University Medical Center, Leiden, The Netherlands., Beets-Tan RGH; GROW Research Institute for Oncology and Reproduction, Maastricht University, Maastricht, The Netherlands.; Radiology Department, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark., van den Broek D; Department of Laboratory Medicine, Netherlands Cancer Institute, Amsterdam, The Netherlands., Trebeschi S; GROW Research Institute for Oncology and Reproduction, Maastricht University, Maastricht, The Netherlands. stefano.trebeschi@maastrichtuniversity.nl.; Radiology Department, Netherlands Cancer Institute, Amsterdam, The Netherlands. stefano.trebeschi@maastrichtuniversity.nl.
المصدر: Journal of cancer research and clinical oncology [J Cancer Res Clin Oncol] 2024 Jun 26; Vol. 150 (6), pp. 329. Date of Electronic Publication: 2024 Jun 26.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 7902060 Publication Model: Electronic Cited Medium: Internet ISSN: 1432-1335 (Electronic) Linking ISSN: 01715216 NLM ISO Abbreviation: J Cancer Res Clin Oncol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Berlin ; New York : Springer-Verlag.
مواضيع طبية MeSH: Carcinoma, Non-Small-Cell Lung*/blood , Carcinoma, Non-Small-Cell Lung*/drug therapy , Carcinoma, Non-Small-Cell Lung*/pathology , Carcinoma, Non-Small-Cell Lung*/therapy , Carcinoma, Non-Small-Cell Lung*/mortality , Lung Neoplasms*/blood , Lung Neoplasms*/drug therapy , Lung Neoplasms*/pathology , Lung Neoplasms*/therapy , Lung Neoplasms*/mortality , Biomarkers, Tumor*/blood , Immune Checkpoint Inhibitors*/therapeutic use , Disease Progression* , Immunotherapy*/methods , Response Evaluation Criteria in Solid Tumors*, Humans ; Male ; Retrospective Studies ; Female ; Middle Aged ; Aged ; Adult ; Aged, 80 and over ; Prognosis
مستخلص: Purpose: In this study, we aimed to evaluate the potential of routine blood markers, serum tumour markers and their combination in predicting RECIST-defined progression in patients with stage IV non-small cell lung cancer (NSCLC) undergoing treatment with immune checkpoint inhibitors.
Methods: We employed time-varying statistical models and machine learning classifiers in a Monte Carlo cross-validation approach to investigate the association between RECIST-defined progression and blood markers, serum tumour markers and their combination, in a retrospective cohort of 164 patients with NSCLC.
Results: The performance of the routine blood markers in the prediction of progression free survival was moderate. Serum tumour markers and their combination with routine blood markers generally improved performance compared to routine blood markers alone. Elevated levels of C-reactive protein (CRP) and alkaline phosphatase (ALP) ranked as the top predictive routine blood markers, and CYFRA 21.1 was consistently among the most predictive serum tumour markers. Using these classifiers to predict overall survival yielded moderate to high performance, even when cases of death-defined progression were excluded. Performance varied across the treatment journey.
Conclusion: Routine blood tests, especially when combined with serum tumour markers, show moderate predictive value  of RECIST-defined progression in NSCLC patients receiving immune checkpoint inhibitors. The relationship between overall survival and RECIST-defined progression may be influenced by confounding factors.
(© 2024. The Author(s).)
References: Nat Mach Intell. 2020 Jan;2(1):56-67. (PMID: 32607472)
Cancer. 2019 Jan 1;125(1):127-134. (PMID: 30329148)
Front Oncol. 2022 Jul 18;12:791496. (PMID: 35924149)
BMC Cancer. 2022 Sep 29;22(1):1022. (PMID: 36171546)
Cancer Imaging. 2018 Dec 11;18(1):50. (PMID: 30537991)
Lancet Oncol. 2017 Mar;18(3):e143-e152. (PMID: 28271869)
Cancer Immunol Immunother. 2020 Sep;69(9):1813-1822. (PMID: 32350592)
ESMO Open. 2019 Aug 16;4(4):e000531. (PMID: 31555483)
Pathol Oncol Res. 2020 Jan;26(1):327-333. (PMID: 30232703)
Eur J Cancer. 2009 Jan;45(2):228-47. (PMID: 19097774)
Eur Rev Med Pharmacol Sci. 2023 Oct;27(5 Suppl):86-94. (PMID: 37869953)
Lung Cancer. 2019 Aug;134:59-65. (PMID: 31319996)
Ther Innov Regul Sci. 2021 Nov;55(6):1111-1121. (PMID: 34228319)
Sci Rep. 2022 Oct 21;12(1):17670. (PMID: 36271096)
Oncol Lett. 2023 Mar 03;25(4):154. (PMID: 36936017)
Cancer Rep (Hoboken). 2022 Oct;5(10):e1578. (PMID: 35075804)
Ann Transl Med. 2018 Apr;6(7):121. (PMID: 29955581)
Cancers (Basel). 2020 Aug 17;12(8):. (PMID: 32824580)
Eur J Cancer. 2016 Jan;53:5-15. (PMID: 26687017)
Tumour Biol. 2021;43(1):115-127. (PMID: 34219680)
Transl Lung Cancer Res. 2013 Oct;2(5):382-97. (PMID: 25806257)
Transl Cancer Res. 2023 Oct 31;12(10):2932-2945. (PMID: 37969388)
Front Oncol. 2021 Mar 02;11:609054. (PMID: 33738253)
Abdom Radiol (NY). 2019 Feb;44(2):766-774. (PMID: 30196362)
J Transl Med. 2023 Mar 5;21(1):174. (PMID: 36872371)
Heliyon. 2022 Oct 04;8(10):e10932. (PMID: 36254284)
Sci Transl Med. 2014 Feb 19;6(224):224ra24. (PMID: 24553385)
Front Oncol. 2021 Jul 26;11:672916. (PMID: 34381708)
Acad Radiol. 2019 Apr;26(4):489-501. (PMID: 29934024)
Clin Cancer Res. 2020 Jun 15;26(12):2849-2858. (PMID: 32046999)
Clin Pharmacol Ther. 2020 Dec;108(6):1274-1288. (PMID: 32564368)
Clin Cancer Res. 2022 Dec 1;28(23):5136-5148. (PMID: 36166003)
Cancer J. 2009 Sep-Oct;15(5):401-5. (PMID: 19826360)
Ther Adv Med Oncol. 2020 Oct 31;12:1758835920952994. (PMID: 33193825)
Cancer Biomark. 2022;34(4):681-692. (PMID: 35662108)
J Immunother Cancer. 2022 Mar;10(3):. (PMID: 35292517)
Front Oncol. 2022 Jan 10;11:800547. (PMID: 35083155)
Insights Imaging. 2021 Mar 18;12(1):36. (PMID: 33738548)
BMC Cancer. 2023 Oct 6;23(1):944. (PMID: 37803437)
Oncol Lett. 2019 Feb;17(2):1409-1416. (PMID: 30675194)
Eur Radiol. 2018 Sep;28(9):3611-3620. (PMID: 29633000)
J Thorac Oncol. 2018 Jan;13(1):97-105. (PMID: 29170120)
Oncologist. 2019 Aug;24(8):1128-1136. (PMID: 31015312)
Cancer Immunol Immunother. 2021 May;70(5):1177-1188. (PMID: 33113004)
Clin Cancer Res. 2018 May 15;24(10):2268-2275. (PMID: 29326281)
فهرسة مساهمة: Keywords: NSCLC; Blood-based markers; Immunotherapy; Machine learning; Progression-free survival; RECIST
المشرفين على المادة: 0 (Biomarkers, Tumor)
0 (Immune Checkpoint Inhibitors)
تواريخ الأحداث: Date Created: 20240626 Date Completed: 20240626 Latest Revision: 20240711
رمز التحديث: 20240711
مُعرف محوري في PubMed: PMC11208229
DOI: 10.1007/s00432-024-05814-2
PMID: 38922374
قاعدة البيانات: MEDLINE
الوصف
تدمد:1432-1335
DOI:10.1007/s00432-024-05814-2